Tadium Cut With A 5-Year Survival Rate Of <1% From Particularly Poor. In Nsclc, The Five-Year Survival Rate Varies By Stage Of 60-70% For Patients In Stage I To <1% Of Patients With Stage Iv Disease. On Average Untreated Patients With Metastatic Sclc Survive Six Months

while the median survival time with treatment is approximately 9 months. Recently, the survival rate has improved in NSCLC both early and late stage. findings show

that the survival in early stage disease (stage IB-IIIB) improves

when a platinum-based chemotherapy is performed after surgical resection. In addition, targeted treatments have improved survival in patients with stage IV disease

especially in patients with EGFR mutation